Table 3. Comparison of characteristics of patients stratified by number of mutations.
| Characteristics | No mutation (n=47) |
One mutation (n=63) |
Two mutations (n=33) |
Three or more mutations (n=11) |
P value |
|---|---|---|---|---|---|
| Age (years), mean ± SD | 63.1±11.4 | 62.6±13.8 | 62.9±13.1 | 60.7±7.54 | 0.96 |
| Sex, n (%) | 0.81 | ||||
| Male | 28 (59.6) | 34 (54.0) | 17 (51.5) | 5 (45.5) | |
| Female | 19 (40.4) | 29 (46.0) | 16 (48.5) | 6 (54.5) | |
| Histological type, n (%) | 0.18 | ||||
| AC | 38 (80.9) | 46 (73.0) | 30 (90.9) | 8 (72.7) | |
| SCC | 9 (19.1) | 17 (27.0) | 3 (9.1) | 3 (27.3) | |
| Stage at diagnosis, n (%) | 0.86 | ||||
| I and II | 6 (12.8) | 11 (17.5) | 7 (21.2) | 1 (9.1) | |
| III | 10 (21.3) | 12 (19.0) | 4 (12.1) | 3 (27.3) | |
| IV | 31 (66.0) | 40 (63.5) | 22 (66.7) | 7 (63.6) | |
| PD-L1 status (%), mean ± SD | 19.2±28.6 | 35.7±38.8 | 35.3±35.7 | 43.0±42.4 | 0.07 |
| PD-L1 status, n (%) | |||||
| <1% | 15 (31.9) | 16 (25.4) | 11 (33.3) | 3 (27.3) | 0.86 |
| 1% to 50% | 18 (38.3) | 17 (27.0) | 8 (24.2) | 3 (27.3) | 0.41 |
| >50% | 8 (17.0) | 22 (34.9) | 12 (36.4) | 4 (36.4) | 0.14 |
| Missing | 6 (12.8) | 8 (12.7) | 2 (6.1) | 1 (9.1) | – |
| ECOG, n (%) | |||||
| 0 | 23 (48.9) | 30 (47.6) | 11 (33.3) | 5 (45.5) | 0.76 |
| 1 | 7 (14.9) | 14 (22.2) | 1 (3.0) | 1 (9.1) | 0.33 |
| 2 | 3 (6.4) | 2 (3.2) | 2 (6.1) | 0 (0.0) | 0.48 |
| Not available | 14 (29.8) | 17 (27.0) | 19 (57.6) | 5 (45.5) | – |
Comparison of baseline characteristics and clinicopathological features stratified by number of mutations. Group no mutation refers to patients without any detected mutation. Metric variables reported as means with SD with P values from t-test. Categorical variables reported as absolute and relative frequencies with P value from χ2-test and Fisher’s exact test (cell number <6). SD, standard deviation; AC, adenocarcinoma; SCC, squamous cell carcinoma; ECOG, Eastern Cooperative Oncology Group.